Rita Santos

Rita Santos

Auto-generated profile, based on publicly available information

Rita Santos

Owkin

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RSRita Santos
Rita Santos
OUOleg Ursu
Oleg Ursu
AGAnna Gaulton
Anna Gaulton
ABA. Patrícia Bento
A. Patrícia Bento
RDRamesh S. Donadi
Ramesh S. Donadi
JOJohn Overington
John Overington

11 May 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe Multiple Tissue Human Expression Resource (MuTHER) Consortium
The Multiple Tissue Human Expression Resource (MuTHER) Consortium
SSSo-Youn Shin
So-Youn Shin
EFEric B Fauman
Eric B Fauman
APAnn-Kristin Petersen
Ann-Kristin Petersen
JKJan Krumsiek
Jan Krumsiek
NSNicole Soranzo
Nicole Soranzo
Nicole Soranzo, Tim Spector, Gabi Kastenmüller and colleagues report a large-scale analysis of genetic variants influencing human blood metabolite levels. They identify genome-wide significant associations at 145 loci, providing a framework for exploring relationships between genetic variation, metabolism and complex disease. Genome-wide association scans with high-throughput metabolic profiling provide unprecedented insights into how genetic variation influences metabolism and complex disease. Here we report the most comprehensive exploration of genetic loci influencing human metabolism thus far, comprising 7,824 adult individuals from 2 European population studies. We report genome-wide significant associations at 145 metabolic loci and their biochemical connectivity with more than 400 metabolites in human blood. We extensively characterize the resulting in vivo blueprint of metabolism in human blood by integrating it with information on gene expression, heritability and overlap with known loci for complex disorders, inborn errors of metabolism and pharmacological targets. We further developed a database and web-based resources for data mining and results visualization. Our findings provide new insights into the role of inherited variation in blood metabolic diversity and identify potential new opportunities for drug development and for understanding disease.

7 November 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ABA. Patrícia Bento
A. Patrícia Bento
AGAnna Gaulton
Anna Gaulton
AHAnne Hersey
Anne Hersey
LBLouisa J. Bellis
Louisa J. Bellis
JCJon Chambers
Jon Chambers
JOJohn Overington
John Overington
ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 Nucleic Acids Research Database Issue. Since then, a variety of new data sources and improvements in functionality have contributed to the growth and utility of the resource. In particular, more comprehensive tracking of compounds from research stages through clinical development to market is provided through the inclusion of data from United States Adopted Name applications; a new richer data model for representing drug targets has been developed; and a number of methods have been put in place to allow users to more easily identify reliable data. Finally, access to ChEMBL is now available via a new Resource Description Framework format, in addition to the web-based interface, data downloads and web services.

29 March 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
CFChris Finan
Chris Finan
AGAnna Gaulton
Anna Gaulton
FKFelix A. Kruger
Felix A. Kruger
RLR. Thomas Lumbers
R. Thomas Lumbers
TSTina Shah
Tina Shah
JRJuan Pablo Pablo Casas Rodriguez
Juan Pablo Pablo Casas Rodriguez
The druggable genome and genome-wide association study data reveal new drug development and repurposing opportunities.

14 February 2018 in MedChemComm
Verified
Journal Article
Closed access
PDF file
KBKristin K. Brown
Kristin K. Brown
MHMichael M. Hann
Michael M. Hann
ALAmi S. Lakdawala
Ami S. Lakdawala
RSRita Santos
Rita Santos
PTPamela J. Thomas
Pamela J. Thomas
KTKieran Todd
Kieran Todd
The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project. This perspective considers differing aspects of tractability and how it can be assessed using in silico and experimental approaches. We also share some of our experiences in using these approaches.

9 November 2009 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
RSRita Santos
Rita Santos
JHJozef Hritz
Jozef Hritz
COChris Oostenbrink
Chris Oostenbrink